{
    "clinical_study": {
        "@rank": "154810", 
        "arm_group": [
            {
                "arm_group_label": "Arm A-Apixaban", 
                "arm_group_type": "Experimental", 
                "description": "Solution Apixaban 5 mg ( 0.4 mg/ml oral solution x 12.5 ml) through mouth or oral syringe"
            }, 
            {
                "arm_group_label": "Arm B-Apixaban", 
                "arm_group_type": "Experimental", 
                "description": "Oral Solution Apixaban 5 mg single dose (0.4 mg/mL oral solution x 12.5 mL) after 180 mL of Boost Plus\u00ae, followed by 60 mL of Boost Plus\u00ae via same NGT"
            }, 
            {
                "arm_group_label": "Arm C-Apixaban", 
                "arm_group_type": "Experimental", 
                "description": "Single dose crushed Apixaban tablet 5 mg (5 mg tablet crushed and suspended in 60 mL Dextrose 5% in water (D5W)) through NGT"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the bioavailability of Apixaban oral solution\n      administered through an Nasogastric Tube (NGT) in the presence of Boost\u00ae Plus and Apixaban\n      administered as crushed tablet through a nasogastric tube relative to Apixaban solution\n      administered orally in healthy subjects."
        }, 
        "brief_title": "Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects", 
        "completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Subjects", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy subjects as determined by no clinically significant deviation from normal in\n             medical history, physical examination, ECGs, and clinical laboratory determinations\n\n        Exclusion Criteria:\n\n          -  Any significant acute or chronic medical illness\n\n          -  Any history or evidence of abnormal bleeding or coagulation disorders, intracranial\n             hemorrhage, or abnormal bleeding (including heavy menstrual bleeding that has\n             resulted in anemia within the past 1 year) or coagulation disorders in a first degree\n             relative"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034591", 
            "org_study_id": "CV185-111"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm A-Apixaban", 
                "Arm B-Apixaban", 
                "Arm C-Apixaban"
            ], 
            "intervention_name": "Apixaban", 
            "intervention_type": "Drug", 
            "other_name": "BMS-562247"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 10, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78209"
                }, 
                "name": "Healthcare Discoveries, LLC D/B/A Icon Development Solutions"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Bioavailability of Apixaban Oral Solution Administered Through a Nasogastric Tube in the Presence of Boost\u00ae Plus and Apixaban Administered as Crushed Tablet Through a Nasogastric Tube Relative to Apixaban Oral Solution in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Bioavailability of Apixaban oral solution (OS) administered through NGT in the presence of Boost Plus\u00ae relative to Apixaban solution administered orally in healthy subjects", 
            "safety_issue": "No", 
            "time_frame": "Up to Day 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034591"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Bioavailability of Apixaban crushed tablet administered through NGT relative to Apixaban solution administered orally in healthy subjects", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 12"
            }, 
            {
                "measure": "Maximum observed plasma concentration (Cmax) of Apixaban will be derived from plasma concentration versus time", 
                "safety_issue": "No", 
                "time_frame": "48 timepoints up to Day 12"
            }, 
            {
                "measure": "Time of maximum observed plasma concentration (Tmax) of Apixaban will be derived from plasma concentration versus time", 
                "safety_issue": "No", 
                "time_frame": "48 timepoints up to Day 12"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from zero to the last time of last quantifiable concentration [AUC(0-T)] of Apixaban will be derived from plasma concentration versus time", 
                "safety_issue": "No", 
                "time_frame": "48 timepoints up to Day 12"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of Apixaban will be derived from plasma concentration versus time", 
                "safety_issue": "No", 
                "time_frame": "48 timepoints up to Day 12"
            }, 
            {
                "measure": "Plasma elimination half-life (T-HALF) of Apixaban will be derived from plasma concentration versus time", 
                "safety_issue": "No", 
                "time_frame": "48 timepoints up to Day 12"
            }, 
            {
                "measure": "Relative bioavailability as calculated by ratio of AUC(INF) (Frel) of Apixaban will be derived from plasma concentration versus time", 
                "safety_issue": "No", 
                "time_frame": "48 timepoints up to Day 12"
            }, 
            {
                "measure": "Safety assessed by incidence of adverse events, results of vital sign measurements, electrocardiograms (ECGs), physical examinations, and clinical laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 12"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}